For those living with genetic disease, the advent of gene therapy represents an end to years of repeated treatment and daily disease management. Using gene editing tools, patient cells can be modified to provide long term therapeutic benefit that cures or mitigates disease. In particular, clustered regularly interspaced short palindromic repeats (CRISPR)/Cas9 technology allows us to make precise genetic changes to cells for therapeutic benefit. During CRISPR gene editing, single guide RNA (sgRNA) directs Cas9 nuclease to make a double-stranded cut to DNA at a precise location in the genome. A DNA repair cassette delivered by recombinant adeno-associated virus (rAAV) is then inserted at the cut site via homologous recombination. This repair cassette can be designed to contain a therapeutic gene which can be expressed at physiological levels, under the control of endogenous regulatory elements. Monogenic disorders of the blood and immune system are severe diseases with limited therapeutic options. While allogeneic hematopoietic stem cell transplantations (HSCT) have historically been used to treat blood and immune disorders, the rise of CRISPR/Cas9 technology has enabled us to modify a patient's own stem cells for autologous transplantation, thereby circumventing the challenges associated with rejection. Hematopoietic stem and progenitor cells (HSPCs) are particularly amenable to gene therapy because we can isolate, culture, and modify them ex vivo. This dissertation explores CRISPR/Cas9 based gene editing as a new therapeutic modality for two primary immune regulatory disorders caused by mutations in the FOXP3 and IL-10 genes, respectively. The goal of this therapeutic modality is to engraft gene edited patient HSPCs to enable healthy hematopoietic reconstitution, curing the disease. The gene editing strategy was validated through assaying the phenotype and function of edited primary T cells; the engraftment and differentiation potential of edited HSPCs were subsequently confirmed in the NSG-SGM3 humanized mouse model. Further, CRISPR/Cas9 knockout experiments elucidated the mechanisms of dysregulation in specific immune subsets, advancing our understanding of the role of FOXP3 and IL-10 in health and disease. Another aspect of bringing cell and gene therapies to the clinic is the complexity and cost of manufacturing. An understated factor that could expedite patient access to gene therapies is robust and cost-efficient manufacturing processes. The final segment of this dissertation applies a regression-based approach to understand key factors influencing gene editing frequencies in CD4+ T cells. Editing frequencies across varying guide and rAAV concentrations were linked to a cost of raw materials analysis model to provide information on the cost drivers of gene targeting and to predict cost-optimal editing conditions for cell therapy manufacturing.